• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Seven drugs approved for NHS Scotland use

Seven drugs approved for NHS Scotland use

September 8, 2015
CenterWatch Staff

Cost regulators in Scotland have given their endorsement to NHS Scotland use of seven new drugs including treatments for blood cancer, ovarian cancer and hepatitis C.

The medications and their uses are listed below:

• Avastin (bevacizumab) from Roche can now be routinely used by ovarian cancer patients, although only when combined with paclitaxel. But backing from the Scottish Medicines Consortium (SMC), which follows a rejection earlier in the year, depends upon continued availability of a Patient Access Scheme (PAS) to improve the drug’s cost-effectiveness.

• Elvanse Adult (lisdexamfetamine) from Shire has been endorsed as part of a program of treatment for adults suffering from attention deficit hyperactivity disorder that is at least moderately severe. When the medicine is taken as a once-daily tablet, it can make it easier for patients and their caregivers to monitor and manage treatment.

• Eylea (aflibercept) from Bayer has been green-lighted as a treatment for impaired vision caused by macular oedema that follows blockage of either the main vein carrying blood from the retina (central retinal vein occlusion) or of tinier branch veins (branch retinal vein occlusion). The approval expands the options for improving vision in patients who do not respond or cannot take current therapies. Its acceptance also is dependent on a PAS to secure value for money.

• Harvoni (ledipasvir-sofosbuvir) from Gilead has been approved for use to treat genotype 3 forms of chronic hepatitis C. Currently, there are only a few treatment options for that subset of patients, and ledipasvir-sofosbuvir might offer a potential cure, according to the SMC. The drug currently is available in Scotland for routine treatments of genotypes 1 and 4 of the disease.

• Januvia (sitagliptin) from Merck Sharp & Dohme can now be accessed via NHS Scotland by patients with type II diabetes, who are not maintaining their blood level targets on insulin alone, as a way to help control their disease. Previously, the SMC accepted the drug for use when combined with a sulfonylurea, and for restricted use with metformin and as monotherapy.

• Signifor (pasireotide) from Novartis was approved for the treatment of adults with acromegaly, a rare condition generally caused by a non-cancerous tumor on the pituitary gland. For those patients, surgery either is not an option or has failed; in addition, the patients are inadequately controlled on treatment with a different somatostatin analogue.

• Velcade (bortezomib) from Janssen-Cilag now can be used to treat the aggressive and rare blood cancer mantle cell lymphoma alongside rituximab, cyclophosphamide, doxorubicin and prednisone, in untreated adults who are unable to have blood stem-cell transplantation. The SMC has said the drug offers patients with limited treatment options the possibility of improvement in quality of life, as well as life expectancy.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing